Literature DB >> 8521592

Pseudohyperphosphatemia.

A J Larner1.   

Abstract

OBJECTIVE: To review instances of spurious elevation of inorganic phosphate measurements due to interference with analytical methods.
METHODS: SElective literature review.
RESULTS: Depending on the method used to measure inorganic phosphate, several factors have been reported to produce spurious elevations, including paraproteinemia, hyperlipidemia, hemolysis, and hyperbilirubinemia. Of these, paraproteinemia is probably the commonest.
CONCLUSION: Both clinical biochemists and clinicians should be aware of the phenomenon of pseudohyperphosphatemia. Clinically unexplained persistent hyperphosphatemia should initiate a search for potential causes of pseudohypophosphatemia, especially paraproteinemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521592     DOI: 10.1016/0009-9120(95)00013-y

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Spurious hyperphosphatemia in patients on hemodialysis with catheters.

Authors:  Brigitte Schiller; Bhupinder Virk; Martin Blair; Amy Wong; John Moran
Journal:  Am J Kidney Dis       Date:  2008-06-05       Impact factor: 8.860

2.  Spurious hyperphosphatemia in a case of multiple myeloma.

Authors:  Sutirtha Chakraborty; Susruta Sen; Debkishore Gupta; Sidhartha Sankar Ghosh; Prasad Sawant; Mandrita Das
Journal:  Indian J Clin Biochem       Date:  2013-08-08

Review 3.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

4.  PSEUDOHYPOPHOSPHATEMIA IN A PATIENT WITH MULTIPLE MYELOMA.

Authors:  Lawrence Wen Wu; Tak-Shun Choi; Monica Barbosa; Hyemi Chong; Ashley Garland Wallace Wu; Kyaw K Soe
Journal:  AACE Clin Case Rep       Date:  2020-08-06

5.  Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.

Authors:  Nicole M Bohm; Katherine C Hoover; Amy E Wahlquist; Yusheng Zhu; Juan Carlos Q Velez
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

6.  Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.

Authors:  Jason W Lane; Nadja N Rehak; Glen L Hortin; Theoklis Zaoutis; Philip R Krause; Thomas J Walsh
Journal:  Clin Chim Acta       Date:  2007-08-30       Impact factor: 3.786

7.  A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway.

Authors:  Joseph Wang; Beth Vogt; Sidharth Kumar Sethi; Matthew G Sampson; Virginia Vega-Warner; Edgar A Otto; Rupesh Raina
Journal:  Kidney Int Rep       Date:  2017-05-17

8.  Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers.

Authors:  Monique Albersen; Arend Bökenkamp; Hans Schotman; Stephanie Smetsers
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.